GSA Capital Partners’s Kyntra Bio KYNB Stock Holding History

GSA Capital Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119K	Buy	+15,697	New	+$110K	0.01%	1610
2024 Q4	–	Sell	-43,835	Closed	-$438K	–	1733
2024 Q3	$438K	Sell	43,835 -9,218	-17%	-$139K	0.03%	1001
2024 Q2	$1.18M	Buy	+53,053	New	+$1.64M	0.08%	396
2023 Q3	–	Sell	-3,003	Closed	-$203K	–	1623
2023 Q2	$203K	Buy	+3,003	New	+$1.24M	0.02%	1261
2022 Q3	–	Sell	-1,571	Closed	-$415K	–	1633
2022 Q2	$415K	Buy	+1,571	New	+$401K	0.06%	613
2019 Q4	–	Sell	-953	Closed	-$881K	–	1520
2019 Q3	$881K	Buy	+953	New	+$1.05M	0.12%	222

Other funds holding KYNB

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

GSA Capital Partners's KYNB Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Kyntra Bio (KYNB) in Q2 2026: 15,697 shares worth $119K. The stake represents 0.01% of the portfolio and ranks #1610 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in KYNB as recently as Q3 2024.

GSA Capital Partners first reported a position in KYNB in Q3 2019 and has held it in 6 quarters since. The position peaked at $1.18M in Q2 2024. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

GSA Capital Partners held 15,697 shares of Kyntra Bio worth $119K as of Q2 2026.
Kyntra Bio was a new GSA Capital Partners position in Q2 2026.
Kyntra Bio made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1610 holding.
GSA Capital Partners first reported a position in Kyntra Bio in Q3 2019 and has held it in 6 quarters since.
GSA Capital Partners's Kyntra Bio position peaked at $1.18M in Q2 2024.
27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.